Passage Bio Presents Preclinical And Interim Clinical Data As Part Of An Oral Presentation At ESGCT 31St Annual Congress Being Held October 22-25, 2024, In Rome, Italy

Benzinga · Oct 24 19:12

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant).

Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation in Grn knockout mice, and achieved widespread vector distribution throughout the nervous system in non-human primates

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Passage Bio Presents Preclinical And Interim Clinical Data As Part Of An Oral Presentation At ESGCT 31St Annual Congress Being Held October 22-25, 2024, In Rome, Italy

Risk Disclaimer